News briefs...

Published: 1-Mar-2004
Regulatory


Australian company Vital Health Sciences (VHS) has filed patents for a drug to prevent and alleviate atherosclerosis. Patent for the drug also covers its use to treat Alzheimer's disease, diabetes and leukaemia. VHS said there were no drugs on the market that treated atherosclerosis directly, but treated risk factors associated with heart disease. The company intends to start pre-clinical trials on atherosclerosis before July.

Emergency contraceptive Postinor-2 became available over the counter in Australia from the beginning of the year. Pharmacists who are morally opposed to selling the pills can refuse to dispense the drug but may leave themselves open to legal action.

Indian-based generics manufacturer Dr Reddy's Laboratories (DRL) has filed an abbreviated new drug application (Anda) with the US FDA for sumatriptan succinate oral tablets. The company notified GSK, which responded by filing a lawsuit against Dr Reddy's alleging patent infringement. Sumatriptan succinate is the generic version of GSK's Imitrex, used to treat migraine.

Japanese companies Sankyo and Fujisawa Pharmaceutical will jointly begin selling a new antibiotic from Aventis Pharma used to treat mild and medium severity respiratory infections. The companies will market the product under the brand name Ketek and will compete in the same geographic areas. They project annual sales of €74m each. Aventis sells Ketek in Europe and Latin America.

See more

You may also like

Manufacturing

Signal Group launches MCERTS approved VOC emissions monitor

Read more
New SOLAR CEMNEX analyser offers advanced compliance and connectivity features

Trending Articles

  1. Douglas Pharmaceuticals sets new benchmark for capsule quality with CI Precision Partnership delivers compliance confidence, efficiency gains and reduced waste
  2. Balancing innovation and accessibility in amino acid testing Butterworth Laboratories expands analytical capabilities to support compliance with Ph. Eur. standards
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    Quality management during manufacturing changes: part I Change is a universal constant and continues to accelerate in the realms of pharmaceutical, medical device and in-vitro diagnostic manufacturers who face ever-increasing pressure to optimise costs while maintaining high product quality and patient safety standards
  4. NICE recommends enfortumab vedotin with KEYTRUDA for adults in England/Wales with untreated metastatic urothelial cancer The results from the Phase III study EV-302/KN-A39 showed nearly a doubling of survival rates in patients compared with those who received platinum-based chemotherapy, which is the current standard of care in the UK
  5. FDA makes groundbreaking decision to waive clinical efficiency studies for monoclonal antibody biosimilars The University of Illinois secured the first-ever FDA acceptance to waive clinical efficiency studies (CESs) for the biological drugs

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Manufacturing

Signal Group launches MCERTS approved VOC emissions monitor

New SOLAR CEMNEX analyser offers advanced compliance and connectivity features
You need to be a subscriber to read this article.
Click here to find out more.
Packaging

Cloud labelling and serialisation: the new frontline of traceability in drug delivery

As drug delivery evolves to accommodate a new wave of data-driven innovation, the need for traceability and compliance throughout the supply chain is paramount. Innovative cloud-based solutions enable pharmaceutical companies to navigate these demands with confidence
Regulatory

Novo Nordisk’s oral semaglutide scores EU approval for cardiovascular benefits

Rybelsus is now the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke
Manufacturing

Douglas Pharmaceuticals sets new benchmark for capsule quality with CI Precision

Partnership delivers compliance confidence, efficiency gains and reduced waste
Regulatory

New NICE thresholds: good news for rare disease drugs but process remains complex

Recent changes introduced by NICE will ultimately see more ultra-rare disease drugs get to market, but Dan Williams, CEO at SynaptixBio, says the process remains challenging
Manufacturing

Balancing innovation and accessibility in amino acid testing

Butterworth Laboratories expands analytical capabilities to support compliance with Ph. Eur. standards
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Quality management during manufacturing changes: part I

Change is a universal constant and continues to accelerate in the realms of pharmaceutical, medical device and in-vitro diagnostic manufacturers who face ever-increasing pressure to optimise costs while maintaining high product quality and patient safety standards
Subscribe now